Novel approaches to therapeutic cancer vaccines.
Novel approaches to therapeutic cancer vaccines.
复制标题
DOI：
10.1586/14760584.2.4.517
复制
发表时间：
2003-08-01
影响因子：
6.2
通讯作者：
Hellstrom, Ingegerd
中科院分区：
文献类型：
--
作者：
Hellstrom, Karl Erik;Hellstrom, Ingegerd
尽管肿瘤疫苗已经研究了几十年，但还没有疫苗被批准作为临床产品。然而，免疫学和肿瘤生物学的最新进展证明了新的兴趣。首先，癌细胞表达许多可以被免疫系统识别的抗原，其中一些具有高肿瘤选择性。其次，免疫调节的知识，包括共刺激信号的重要性，已成功地应用于肿瘤的研究。第三，已经确定了肿瘤如何逃脱免疫控制的机制，为发现减少其影响的药物奠定了基础。由于治疗性肿瘤疫苗接种，已经实现了对已建立的小鼠肿瘤的排斥，并且在人类中的疫苗试验中有令人鼓舞的发现。
Although tumor vaccines have been studied for decades, there is no vaccine approved as a clinical product. Nevertheless, recent advances in immunology and tumor biology justify a renewed interest. First, cancer cells express many antigens that can be recognized by the immune system, some with high tumor selectivity. Second, knowledge about immune regulation, including the importance of costimulatory signals, has been successfully applied to the studies of tumors. Third, mechanisms of how tumors can escape from immunological control have been identified, setting the stage to discover agents to decrease their impact. Rejection of established mouse tumors has been accomplished as a result of therapeutic tumor vaccination and there are encouraging findings from vaccine trials in humans.